

Table S1. Resting cardiovascular and cerebrovascular measures at the start (PRE) and following (POST) the 8 week Control and Intervention trials (mean \pm SD).

	Control		Within-Group Differences	Intervention		Within-Group Differences	Between-Group Differences	Cohen's <i>d</i>
	PRE	POST		PRE	POST			
Cardiovascular								
HR (bpm)	62 \pm 10	62 \pm 12	0 \pm 5	58 \pm 11	57 \pm 11	-1 \pm 7	-1 \pm 8	0.17
SBP (mmHg)	125 \pm 14	121 \pm 15	-4 \pm 5	120 \pm 11	122 \pm 14	2 \pm 8	6 \pm 11	0.93
DBP (mmHg)	77 \pm 9	75 \pm 10	-2 \pm 6	73 \pm 10	74 \pm 8	1 \pm 7	3 \pm 9	0.48
MAP (mmHg)	93 \pm 10	90 \pm 11	-3 \pm 4	88 \pm 9	90 \pm 10	2 \pm 6	5 \pm 6	1.02
Cerebrovascular								
MCAv ($\text{cm} \cdot \text{s}^{-1}$)	70.1 \pm 12.0	68.3 \pm 8.4	-1.8 \pm 7.0	67.4 \pm 14.1	66.4 \pm 9.1	-1.0 \pm 8.3	0.8 \pm 11.1	0.11
PCAv ($\text{cm} \cdot \text{s}^{-1}$)	52.4 \pm 13.3	51.3 \pm 9.8	-1.1 \pm 7.8	48.9 \pm 9.1	50.2 \pm 10.9	1.3 \pm 9.1	2.4 \pm 13.7	0.30
PETCO ₂ (mmHg)	38 \pm 4	39 \pm 4	1 \pm 2	36 \pm 5	37 \pm 5	1 \pm 4	0 \pm 5	0.00

HR—heart rate, SBP—systolic blood pressure; DBP—diastolic blood pressure, MAP—mean arterial pressure, MCAv—middle cerebral artery blood flow velocity, PCAv—posterior middle cerebral artery blood flow velocity, PETCO₂—pressure of end-tidal carbon dioxide.

Table S2. Measures of cerebrovascular function at the start (PRE) and following (POST) the 8 week Control and Intervention trials (mean \pm SD).

	Control		Within-Group Differences	Intervention		Within-Group Differences	Between-Group Differences	Cohen's <i>d</i>
	PRE	POST		PRE	POST			
MCA CVR								
CVR (R^2)	0.89 \pm 0.05	0.86 \pm 0.07	-0.03 \pm 0.08	0.84 \pm 0.05	0.87 \pm 0.08	0.03 \pm 0.09	0.06 \pm 0.11	0.74
ABS MCAv ($\text{cm} \cdot \text{s}^{-1} \cdot \text{mmHg}^{-1}$)	3.20 \pm 0.89	3.23 \pm 1.27	0.03 \pm 1.06	3.18 \pm 1.09	3.35 \pm 0.61	0.17 \pm 0.83	0.14 \pm 1.11	0.16
REL MCAv (% \cdot mmHg $^{-1}$)	4.61 \pm 0.99	4.69 \pm 1.64	0.08 \pm 1.23	4.85 \pm 1.51	5.14 \pm 1.01	0.29 \pm 1.25	0.21 \pm 1.04	0.18
CCA CVR								
ABS Diameter ($\text{cm} \cdot \text{mmHg}^{-1}$)	0.001 \pm 0.001	0.001 \pm 0.001	0.000 \pm 0.001	0.001 \pm 0.001	0.001 \pm 0.001	0.000 \pm 0.002	0.000 \pm 0.002	0.00
REL Diameter (% \cdot mmHg $^{-1}$)	0.13 \pm 0.13	0.13 \pm 0.09	0.00 \pm 0.14	0.20 \pm 0.18	0.13 \pm 0.19	-0.07 \pm 0.25	-0.07 \pm 0.28	0.37
ABS Blood Flow ($\text{ml} \cdot \text{min}^{-1} \cdot \text{mmHg}^{-1}$)	0.26 \pm 0.22	0.23 \pm 0.21	-0.03 \pm 0.22	0.25 \pm 0.28	0.17 \pm 0.27	-0.08 \pm 0.34	-0.05 \pm 0.42	0.19
REL Blood Flow (% \cdot mmHg $^{-1}$)	2.00 \pm 1.64	1.87 \pm 1.55	-0.13 \pm 1.78	2.06 \pm 2.20	1.38 \pm 1.91	-0.68 \pm 2.48	-0.55 \pm 3.08	0.27
NVC								
ABS Peak PCAv ($\Delta \text{cm} \cdot \text{s}^{-1}$)	9.8 \pm 4.9	10.9 \pm 6.3	1.1 \pm 3.7	6.8 \pm 3.9	6.5 \pm 5.4	-0.3 \pm 7.4	-1.4 \pm 8.0	0.26
REL Peak PCAv (%)	20.6 \pm 12.2	22.7 \pm 13.7	2.1 \pm 8.0	14.7 \pm 8.3	15.4 \pm 13.7	0.7 \pm 17.7	-1.4 \pm 18.0	0.11
ABS Peak MCAv ($\Delta \text{cm} \cdot \text{s}^{-1}$)	6.2 \pm 1.2	6.2 \pm 3.5	0.0 \pm 2.7	4.8 \pm 0.6	5.4 \pm 1.2	0.6 \pm 1.3	0.6 \pm 3.5	0.32
REL Peak MCAv (%)	8.9 \pm 2.0	9.2 \pm 4.2	0.3 \pm 3.0	7.5 \pm 1.7	8.3 \pm 2.5	0.8 \pm 2.1	0.5 \pm 4.6	0.22
CA: 5-sec (LF)								
Phase (degrees)	24.33 \pm 5.30	17.87 \pm 8.20	-6.46 \pm 6.45	24.33 \pm 19.96	24.07 \pm 6.80	-0.26 \pm 16.67	6.19 \pm 16.67	0.53
Gain ($\text{cm} \cdot \text{s}^{-1} \cdot \text{mmHg}^{-1}$)	0.87 \pm 0.17	0.83 \pm 0.12	-0.04 \pm 0.12	0.81 \pm 0.23	0.98 \pm 0.25	0.17 \pm 0.22	0.21 \pm 0.33	1.25
Gain _n (% \cdot mmHg $^{-1}$)	1.38 \pm 0.25	1.36 \pm 0.22	-0.02 \pm 0.18	1.30 \pm 0.26	1.52 \pm 0.37	0.22 \pm 0.35	0.24 \pm 0.49	0.91
Coherence [#]	0.64 \pm 0.11	0.61 \pm 0.07	-	0.69 \pm 0.12	0.61 \pm 0.07	-	-	-
CA: 10-sec (VLF)								
Phase (degrees)	43.72 \pm 15.11	37.53 \pm 10.02	-6.19 \pm 7.75	45.33 \pm 18.89	46.30 \pm 17.94	0.97 \pm 17.11	7.16 \pm 14.41	0.57
Gain ($\text{cm} \cdot \text{s}^{-1} \cdot \text{mmHg}^{-1}$)	0.74 \pm 0.18	0.83 \pm 0.22	0.09 \pm 0.11	0.72 \pm 0.25	0.80 \pm 0.21	0.08 \pm 0.16	-0.01 \pm 0.22	0.08
Gain _n (% \cdot mmHg $^{-1}$)	1.20 \pm 0.30	1.28 \pm 0.29	0.08 \pm 0.19	1.20 \pm 0.28	1.29 \pm 0.29	0.09 \pm 0.15	0.01 \pm 0.27	0.06
Coherence [#]	0.83 \pm 0.15	0.86 \pm 0.08	-	0.88 \pm 0.10	0.89 \pm 0.07	-	-	-

[#]Coherence values were used to accept the validity of gain and phase estimates and not compared.

MCAv—middle cerebral artery blood flow velocity; CVR—cerebrovascular carbon dioxide reactivity; ABS—absolute; REL—relative; CCA—common carotid artery; NVC—neurovascular coupling; PCAv—posterior cerebral artery blood flow velocity; CA—cerebral autoregulation; LF—low frequency, VLF—very low frequency; Gain_n—normalised gain.

Table S3. Measures of mood and work productivity at the start (PRE) and following (POST) the 8 week Control and Intervention trials (mean \pm SD).

	Control		Within-Group Differences	Intervention		Within-Group Differences	Between-Group Differences	Cohen's <i>d</i>
	PRE	POST		PRE	POST			
Mood								
Positive Affect	34.9 \pm 7.9	35.3 \pm 6.1	0.4 \pm 7.0	35.5 \pm 6.7	35.7 \pm 5.5	0.2 \pm 6.3	-0.2 \pm 9.5	0.04
Negative Affect	15.6 \pm 5.2	15.1 \pm 3.6	-0.5 \pm 5.9	15.7 \pm 6.5	15.6 \pm 8.2	-0.1 \pm 9.4	0.4 \pm 12.0	0.05
HWQ								
Productivity	6.9 \pm 1.9	7.1 \pm 1.4	0.2 \pm 1.4	6.6 \pm 1.9	7.5 \pm 1.5	0.9 \pm 1.7	0.7 \pm 2.1	0.47
Concentration/Focus	4.5 \pm 2.5	3.9 \pm 2.4	-0.6 \pm 2.5	4.6 \pm 2.8	3.8 \pm 2.3	-0.6 \pm 2.2	0.0 \pm 4.2	0.00
Impatience/Irritability	3.6 \pm 2.3	2.9 \pm 2.0	-0.7 \pm 2.2	3.7 \pm 2.7	2.8 \pm 1.5	-0.9 \pm 2.5	-0.2 \pm 3.5	0.09
Work Satisfaction	7.0 \pm 1.8	6.7 \pm 2.0	-0.3 \pm 1.4	6.7 \pm 1.8	7.3 \pm 1.5	0.6 \pm 1.7	0.9 \pm 2.2	0.60
Stress	5.4 \pm 2.2	4.4 \pm 2.2	-1.0 \pm 2.0	5.3 \pm 2.9	4.4 \pm 2.2	-0.9 \pm 3.1	0.1 \pm 3.9	0.04
Supervisor Relations	7.0 \pm 2.4	6.9 \pm 2.3	-0.1 \pm 2.9	6.5 \pm 2.6	7.0 \pm 2.5	0.5 \pm 2.5	0.6 \pm 4.1	0.23
Non-work Satisfaction	8.2 \pm 1.6	8.0 \pm 1.5	-0.2 \pm 1.1	7.7 \pm 2.4	8.2 \pm 1.8	0.5 \pm 1.9	0.7 \pm 2.4	0.47

HWQ—Health and Work Questionnaire.